Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1080/14656566.2021.1960311 http://scihub22266oqcxt.onion/10.1080/14656566.2021.1960311 34464223!8425433!34464223     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 243.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Expert+Opin+Pharmacother 2021 ; 22 (18): 2455-2474 Nephropedia Template TP {{tp|p=34464223|t=2021. Pharmacotherapeutic agents for the management of COVID-19 patients with preexisting cardiovascular disease |pdf=|usr=}}{{34464223}} gab.com Text Pharmacotherapeutic agents for the management of COVID-19 patients with preexisting cardiovascular disease JO: Expert Opin Pharmacother http://www.kidney.de/pget.php?&tw=1&pmid=34464223 #FOAvip INTRODUCTION: The coronavirus disease 2019 (COVID-19) pandemic is the largest public health challenge of the twenty-first century. While COVID-19 primarily affects the respiratory system, manifesting as interstitial pneumonitis and severe acute respiratory distress syndrome (ARDS), it also has implications for the cardiovascular system. Moreover, those admitted to hospital with severe COVID-19 are more likely to have cardiovascular comorbidities such as hypertension and diabetes mellitus. The underlying pathophysiology of why COVID-19 onset can further decline cardiac pathologies as well as trigger acute onset of new cardiac complications is not yet well understood. AREAS COVERED: In this review, the authors extensively review literature focused on the current understanding and approaches of managing patients who have underlying cardiovascular diseases and concomitant COVID-19 infection. Furthermore, the authors explore the possible cardiovascular implications of the suggested COVID-19 therapeutic agents that are used to treat this lethal disease. EXPERT OPINION: Current evidence is evolving around the many trialed pharmacotherapeutic considerations for the management of coronavirus disease 2019 (COVID-19) in patients with cardiovascular disease. While we await such data, clinicians should advocate for careful consideration of all concomitant medications for those presenting with COVID-19 on a patient-by-patient basis. Twit Text FOAVip Pharmacotherapeutic agents for the management of COVID-19 patients with preexisting cardiovascular disease ????Expert Opin Pharmacother http://www.kidney.de/pget.php?&tw=1&pmid=34464223 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34464223 #FOAvip English Wikipedia <ref>{{Cite pmid|34464223}}</ref> Pharmacotherapeutic agents for the management of COVID-19 patients with preexisting cardiovascular disease #MMPMID34464223 Khan M; Singh GK; Abrar S; Ganeshan R; Morgan K; Harky A Expert Opin Pharmacother 2021[Dec]; 22 (18): 2455-2474 PMID34464223show ga INTRODUCTION: The coronavirus disease 2019 (COVID-19) pandemic is the largest public health challenge of the twenty-first century. While COVID-19 primarily affects the respiratory system, manifesting as interstitial pneumonitis and severe acute respiratory distress syndrome (ARDS), it also has implications for the cardiovascular system. Moreover, those admitted to hospital with severe COVID-19 are more likely to have cardiovascular comorbidities such as hypertension and diabetes mellitus. The underlying pathophysiology of why COVID-19 onset can further decline cardiac pathologies as well as trigger acute onset of new cardiac complications is not yet well understood. AREAS COVERED: In this review, the authors extensively review literature focused on the current understanding and approaches of managing patients who have underlying cardiovascular diseases and concomitant COVID-19 infection. Furthermore, the authors explore the possible cardiovascular implications of the suggested COVID-19 therapeutic agents that are used to treat this lethal disease. EXPERT OPINION: Current evidence is evolving around the many trialed pharmacotherapeutic considerations for the management of coronavirus disease 2019 (COVID-19) in patients with cardiovascular disease. While we await such data, clinicians should advocate for careful consideration of all concomitant medications for those presenting with COVID-19 on a patient-by-patient basis. |*COVID-19[MESH] |*Cardiovascular Diseases/drug therapy/epidemiology[MESH] |*Cardiovascular System[MESH] |Humans[MESH] |Pandemics[MESH]Pharmacotherapeutic agents for the management of COVID-19 patients wit(epmc).pdf DeepDyve Pubget Overpricing